Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) EBIT (2023 - 2025)

Historic EBIT for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$2.2 million.

  • BioLineRx's EBIT rose 5903.1% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.3 million, marking a year-over-year increase of 6721.37%. This contributed to the annual value of -$20.4 million for FY2024, which is 5893.27% up from last year.
  • Latest data reveals that BioLineRx reported EBIT of -$2.2 million as of Q3 2025, which was up 5903.1% from -$2.3 million recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's EBIT peaked at -$2.2 million during Q3 2025, and registered a low of -$18.6 million during Q4 2023.
  • Its 3-year average for EBIT is -$7.0 million, with a median of -$5.4 million in 2024.
  • The largest annual percentage gain for BioLineRx's EBIT in the last 5 years was 7616.07% (2024), contrasted with its biggest fall of 4177.51% (2024).
  • Quarter analysis of 3 years shows BioLineRx's EBIT stood at -$18.6 million in 2023, then surged by 76.16% to -$4.4 million in 2024, then soared by 50.14% to -$2.2 million in 2025.
  • Its EBIT stands at -$2.2 million for Q3 2025, versus -$2.3 million for Q2 2025 and -$2.4 million for Q1 2025.